If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 August 2018 The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions.
2 May 2018 The European Patent Office has revoked a patent covering Mylan’s EpiPen injector after finding that patent amendments contravened the European Patent Convention (EPC).
17 August 2018 The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions.
2 May 2018 The European Patent Office has revoked a patent covering Mylan’s EpiPen injector after finding that patent amendments contravened the European Patent Convention (EPC).
17 August 2018 The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions.
2 May 2018 The European Patent Office has revoked a patent covering Mylan’s EpiPen injector after finding that patent amendments contravened the European Patent Convention (EPC).